Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
This study has been completed.
Study NCT00181688 Information provided by Massachusetts General Hospital
First Received: September 12, 2005 Last Updated: December 28, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Cancer
Peritoneal Carcinoma
Tubal Carcinoma
Additional conditions recognized in this trial
Carcinoma
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Urogenital Neoplasms
Interventions listed in this trial
Iressa (ZD1839)
Arimidex (Anastrozole)
Additional drug interventions recognized in this trial
Anastrozole
Gefitinib
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Back to top of Main Content
